AngioChem
201 President-Kennedy Avenue
Suite PK-R210
Montreal
Quebec
H2X 3Y7
Canada
Tel: 514-788-7800
Fax: 514-788-7801
Website: http://www.angiochem.com/
45 articles about AngioChem
-
Hong Kong's Xinogen Acquires China Rights to Angiochem Cancer Drug
1/4/2018
Xinogen will make upfront and milestone payments and also pay royalties on sales, though specific details were not disclosed.
-
AngioChem Reports Positive Clinical Data With ANG1005 In Breast Cancer Patients With Leptomeningeal Carcinomatosis
11/20/2015
-
ASCO15: AngioChem Presents ANG1005 Data On Breast Cancer Patients With Brain Metastasis At The 2015 American Society For Clinical Oncology Annual Meeting
6/1/2015
-
AngioChem Publishes Data On ANG4043, A Brain-Penetrant Anti-HER2 Monoclonal Antibody For Treatment Of Brain Metastases
12/9/2014
-
AngioChem's ANG1005 Received Fast Track And Orphan Drug Designation From FDA For The Treatment Of Glioblastoma Multiforme
5/30/2014
-
AngioChem Presents Positive Data On ANG1005 In Brain Mets, Launches Phase 2, Gets Orphan Drug/Fast Track
5/30/2014
-
AngioChem To Present Clinical Data At The American Society of Clinical Oncology 2014 Annual Meeting
5/15/2014
-
Preclinical Data On AngioChem Pain Program Published In Journal Of Clinical Investigation
2/18/2014
-
AngioChem Demonstrates Peptide Antibody Conjugate That Successfully Crosses The Blood Brain Barrier And Increases Survival In HER-2 Positive Brain Tumors
12/16/2013
-
AngioChem To Present Data On Its Lead Oncology Compounds At The 2013 San Antonio Breast Cancer Symposium
12/5/2013
-
AngioChem’s ANG1005 For Primary Brain Cancer And Brain Metastasis Selected As A Top 10 Project To Watch
11/12/2013
-
Phase 2 Clinical Data for AngioChem's Lead Drug Candidate, ANG1005, in Breast Cancer Patients With Brain Metastases Revealed
10/21/2013
-
AngioChem to Present at the American Society of Human Genetics 2013 Annual Meeting
10/17/2013
-
AngioChem to Present at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
10/8/2013
-
AngioChem Announces Presentations at Six Upcoming Conferences
9/26/2012
-
AngioChem Named as One of the “Fierce 15” Biotech Companies of 2012
9/19/2012
-
AngioChem Presents at the 2012 Barriers of the CNS Gordon Research Conference
6/19/2012
-
AngioChem Announces Presentations at Three Upcoming Conferences
5/17/2012
-
AngioChem, GlaxoSmithKline Form $331 Million Pact to Discover and Develop Treatments of Lysosomal Storage Diseases
2/27/2012
-
AngioChem Presents Data Demonstrating the Broad Applicability of Its EPiC Technology to Cross the Blood Brain Barrier
10/24/2011